Groupe la Francaise Purchases 297,049 Shares of Boston Scientific Corporation $BSX

Groupe la Francaise boosted its holdings in Boston Scientific Corporation (NYSE:BSX) by 88.6% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 632,131 shares of the medical equipment provider’s stock after purchasing an additional 297,049 shares during the quarter. Boston Scientific comprises approximately 1.1% of Groupe la Francaise’s investment portfolio, making the stock its 23rd largest holding. Groupe la Francaise’s holdings in Boston Scientific were worth $67,871,000 at the end of the most recent quarter.

Several other institutional investors have also recently bought and sold shares of BSX. Vanguard Group Inc. increased its position in shares of Boston Scientific by 1.9% during the second quarter. Vanguard Group Inc. now owns 137,134,110 shares of the medical equipment provider’s stock worth $14,729,575,000 after acquiring an additional 2,545,381 shares in the last quarter. Geode Capital Management LLC boosted its stake in Boston Scientific by 2.0% during the 2nd quarter. Geode Capital Management LLC now owns 32,424,982 shares of the medical equipment provider’s stock valued at $3,466,320,000 after purchasing an additional 622,602 shares during the last quarter. Norges Bank acquired a new position in Boston Scientific during the 2nd quarter valued at about $2,089,937,000. Invesco Ltd. increased its holdings in Boston Scientific by 5.3% during the 1st quarter. Invesco Ltd. now owns 16,624,940 shares of the medical equipment provider’s stock worth $1,677,124,000 after purchasing an additional 834,274 shares in the last quarter. Finally, Goldman Sachs Group Inc. raised its stake in shares of Boston Scientific by 10.8% in the first quarter. Goldman Sachs Group Inc. now owns 14,143,332 shares of the medical equipment provider’s stock worth $1,426,779,000 after purchasing an additional 1,383,524 shares during the last quarter. Institutional investors and hedge funds own 89.07% of the company’s stock.

Analyst Ratings Changes

BSX has been the topic of several analyst reports. Canaccord Genuity Group reaffirmed a “buy” rating and set a $132.00 target price on shares of Boston Scientific in a research report on Thursday, October 23rd. Erste Group Bank lowered shares of Boston Scientific from a “buy” rating to a “hold” rating in a research note on Friday, October 3rd. Morgan Stanley raised their price target on shares of Boston Scientific from $125.00 to $130.00 and gave the company an “overweight” rating in a research report on Thursday, October 23rd. Wells Fargo & Company boosted their price target on shares of Boston Scientific from $124.00 to $125.00 and gave the stock an “overweight” rating in a report on Thursday, October 23rd. Finally, Royal Bank Of Canada reiterated an “outperform” rating and issued a $125.00 price objective on shares of Boston Scientific in a research note on Monday, September 29th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and two have given a Hold rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average target price of $123.77.

Boston Scientific Stock Performance

NYSE BSX opened at $100.94 on Tuesday. The company has a market capitalization of $149.63 billion, a PE ratio of 53.98, a price-to-earnings-growth ratio of 2.02 and a beta of 0.58. The company has a debt-to-equity ratio of 0.49, a quick ratio of 0.82 and a current ratio of 1.37. Boston Scientific Corporation has a 52-week low of $85.98 and a 52-week high of $109.50. The company has a 50-day simple moving average of $99.25 and a 200 day simple moving average of $102.24.

Boston Scientific (NYSE:BSX) last released its earnings results on Wednesday, October 22nd. The medical equipment provider reported $0.75 earnings per share for the quarter, beating analysts’ consensus estimates of $0.71 by $0.04. Boston Scientific had a net margin of 14.43% and a return on equity of 19.74%. The firm had revenue of $5.07 billion during the quarter, compared to the consensus estimate of $4.97 billion. During the same period in the prior year, the firm earned $0.63 EPS. The company’s revenue was up 20.3% compared to the same quarter last year. Boston Scientific has set its FY 2025 guidance at 3.020-3.040 EPS. Q4 2025 guidance at 0.770-0.790 EPS. On average, research analysts predict that Boston Scientific Corporation will post 2.85 EPS for the current year.

Insiders Place Their Bets

In related news, Director Ellen M. Zane sold 12,891 shares of Boston Scientific stock in a transaction dated Thursday, November 6th. The stock was sold at an average price of $98.28, for a total value of $1,266,927.48. Following the completion of the sale, the director owned 24,134 shares of the company’s stock, valued at approximately $2,371,889.52. This trade represents a 34.82% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, EVP Joseph Michael Fitzgerald sold 50,000 shares of the company’s stock in a transaction dated Monday, November 3rd. The shares were sold at an average price of $99.47, for a total transaction of $4,973,500.00. Following the sale, the executive vice president directly owned 178,342 shares in the company, valued at approximately $17,739,678.74. This trade represents a 21.90% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 125,782 shares of company stock valued at $12,470,814 over the last three months. Company insiders own 0.50% of the company’s stock.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.